期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
After having changed the treatment of heart failure with reduced ejection fraction: what are the latest evidences with sacubitril valsartan? 被引量:5
1
作者 Edgardo Kaplinsky 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2019年第2期151-155,共5页
1 Introduction Sacubitril/valsartan(SV)is a first in class dual action molecule of the neprilysin(NEP)inhibitor prodrug sacubitril(AHU377)and the angiotensin II receptor(Ang-II)type 1 antagonist valsartanJ11 It is the... 1 Introduction Sacubitril/valsartan(SV)is a first in class dual action molecule of the neprilysin(NEP)inhibitor prodrug sacubitril(AHU377)and the angiotensin II receptor(Ang-II)type 1 antagonist valsartanJ11 It is the first angiotensin receptor-neprilysin inhibitor(ARNI)whose pharmacodynamic effects are consistent with a simultaneous stimulation of the natriuretic peptides system(via NEP inhibition)and the blockade of the renin-angiotensin-aldosterone system(valsartan effect)that finally results in systemic vasodilation,increased diuresis and natriuresis,reduction of plasmatic volume and diminution of peripheral vascular resistance. 展开更多
关键词 Heart failure Sacubitril/Valsartan
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部